A hypoxia related long non-coding RNA signature could accurately predict survival outcomes in patients with bladder cancer

References

• Berdik C. Unlocking bladder cancer. Nature. 2017;551(7679):S34–S5.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Comperat EM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. 2019;76(5):639–657.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104.
   PubMed Web of Science ®Google Scholar
• Grayson M. Bladder cancer. Nature. 2017;551(7679):S33–S.
   PubMed Web of Science ®Google Scholar
• Sun Z, Jing C, Xiao C, et al. An autophagy-related long non-coding RNA prognostic signature accurately predicts survival outcomes in bladder urothelial carcinoma patients. Aging (Albany NY). 2020;12(15):15624–15637.
   PubMedGoogle Scholar
• Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540–56.e25.
   PubMed Web of Science ®Google Scholar
• McConkey DJ, Choi W. Molecular subtypes of bladder cancer. Curr Oncol Rep. 2018;20(10):77.
   PubMed Web of Science ®Google Scholar
• Petrova V, Annicchiarico-Petruzzelli M, Melino G, et al. The hypoxic tumour microenvironment. Oncogenesis. 2018;7(1):10.
   PubMedGoogle Scholar
• Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14(6):430–439.
   PubMed Web of Science ®Google Scholar
• Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352(6282):175–180.
   PubMed Web of Science ®Google Scholar
• Mo Z, Yu L, Cao Z, et al. Identification of a hypoxia-associated signature for lung adenocarcinoma. Front Genet. 2020;11:647.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu J, Huang W, et al. Development and validation of a hypoxia-immune-based microenvironment gene signature for risk stratification in gastric cancer. J Transl Med. 2020;18(1):201.
   PubMed Web of Science ®Google Scholar
• Lin W, Wu S, Chen X, et al. Characterization of hypoxia signature to evaluate the tumor immune microenvironment and predict prognosis in glioma groups. Front Oncol. 2020;10:796.
   PubMed Web of Science ®Google Scholar
• Zou Y-F, Rong Y-M, Tan Y-X, et al. A signature of hypoxia-related factors reveals functional dysregulation and robustly predicts clinical outcomes in stage I/II colorectal cancer patients. Cancer Cell Int. 2019;19(1):243.
   PubMed Web of Science ®Google Scholar
• Zhang B, Tang B, Gao J, et al. A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients. J Transl Med. 2020;18(1):342.
   PubMed Web of Science ®Google Scholar
• Boström PJ, Thoms J, Sykes J, et al. Hypoxia marker GLUT-1 (glucose transporter 1) is an independent prognostic factor for survival in bladder cancer patients treated with radical cystectomy. Bladder Cancer. 2016;2(1):101–109.
   PubMed Web of Science ®Google Scholar
• Hoskin PJ, Sibtain A, Daley FM, et al. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer. 2003;89(7):1290–1297.
   PubMed Web of Science ®Google Scholar
• Quan J, Pan X, Zhao L, et al. LncRNA as a diagnostic and prognostic biomarker in bladder cancer: a systematic review and meta-analysis. Onco Targets Ther. 2018;11:6415–6424.
   PubMed Web of Science ®Google Scholar
• Deng S-J, Chen H-Y, Ye Z, et al. Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. Oncogene. 2018;37(44):5811–5828.
   PubMed Web of Science ®Google Scholar
• Hua Q, Mi B, Xu F, et al. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis. Theranostics. 2020;10(11):4762–4778.
   PubMed Web of Science ®Google Scholar
• Liang Y, Song X, Li Y, et al. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis. Mol Cancer. 2020;19(1):85.
   PubMed Web of Science ®Google Scholar
• Sun L, Wang L, Chen T, et al. LncRNA RUNX1-IT1 which is downregulated by hypoxia-driven histone deacetylase 3 represses proliferation and cancer stem-like properties in hepatocellular carcinoma cells. Cell Death Dis. 2020;11(2):95.
   PubMed Web of Science ®Google Scholar
• Zhang J, Jin HY, Wu Y, et al. Hypoxia-induced LncRNA PCGEM1 promotes invasion and metastasis of gastric cancer through regulating SNAI1. Clin Transl Oncol. 2019;21(9):1142–1151.
   PubMed Web of Science ®Google Scholar
• Cao H-L, Liu Z-J, Huang P-L, et al. lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206. Eur Rev Med Pharmacol Sci. 2019;23(3):1012–1021.
   PubMed Web of Science ®Google Scholar
• Dai G, Huang C, Yang J, et al. LncRNA SNHG3 promotes bladder cancer proliferation and metastasis through miR-515-5p/GINS2 axis. J Cell Mol Med. 2020;24(16):9231–9243.
   PubMed Web of Science ®Google Scholar
• Rui X, Wang L, Pan H, et al. LncRNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2/miR-298/CDK9 axis. J Cell Mol Med. 2019;23(2):865–876.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wang W, Lin J, et al. lncRNA CCAT1 promotes bladder cancer cell proliferation, migration and invasion. Int Braz J Urol. 2019;45(3):549–559.
   PubMed Web of Science ®Google Scholar
• Zhuang C, Ma Q, Zhuang C, et al. LncRNA GClnc1 promotes proliferation and invasion of bladder cancer through activation of MYC. Faseb J. 2019;33(10):11045–11059.
   PubMed Web of Science ®Google Scholar
• Chen C, He W, Huang J, et al. LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. Nat Commun. 2018;9(1):3826.
   PubMed Web of Science ®Google Scholar
• Chen C, Luo Y, He W, et al. Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J Clin Invest. 2020;130(1):404–421.
   PubMed Web of Science ®Google Scholar
• Wang X, Li T. Development of a 15-gene signature for predicting prognosis in advanced colorectal cancer. Bioengineered. 2020;11(1):165–174.
   PubMed Web of Science ®Google Scholar
• Zhang F, Wang X, Bai Y, et al. Development and validation of a hypoxia-related signature for predicting survival outcomes in patients with bladder cancer. Frontiers in genetics. 2021, 12:670384.
   Google Scholar
• Wu S, Li X. A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma. Bioengineered. 2021;12(1):1642–1662.
   PubMed Web of Science ®Google Scholar
• Yang W, Soares J, Greninger P, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research. 2013;41(Database issue):D955–61.
   PubMedGoogle Scholar
• Shum B, Larkin J, Turajlic S. Predictive biomarkers for response to immune checkpoint inhibition. Seminars in cancer biology. 2021.
   Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Reports. 2017;18(1):248–262.
   PubMed Web of Science ®Google Scholar
• Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol. 2020;203(5):902–909.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Wang J, Shen C, Dong D, et al. Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer. International immunopharmacology. 2021, 90: 107146.
   Google Scholar
• Tong H, Li T, Gao S, et al. An epithelial-mesenchymal transition-related long noncoding rna signature correlates with the prognosis and progression in bladder cancer patients. Bioscience reports. 2021, 41(1).
   Google Scholar
• Zhou M, Zhang Z, Bao S, et al. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer. Brief Bioinform. 2020, 22(3).
   Web of Science ®Google Scholar
• Zhang H, Zhu C, He Z, et al. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis. J Exp Clin Cancer Res. 2020;39(1):179.
   PubMed Web of Science ®Google Scholar
• Giulietti M, Righetti A, Principato G, et al. LncRNA co-expression network analysis reveals novel biomarkers for pancreatic cancer. Carcinogenesis. 2018;39(8):1016–1025.
   PubMed Web of Science ®Google Scholar
• Feldman SA, Assadipour Y, Kriley I, et al. Adoptive cell therapy--tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors. Semin Oncol. 2015;42(4):626–639.
   PubMed Web of Science ®Google Scholar
• Stroncek DF, Reddy O, Highfill S, et al. Advances in T-cell immunotherapies. Hematol Oncol Clin North Am. 2019;33(5):825–837.
   PubMed Web of Science ®Google Scholar
• Arora S, Velichinskii R, Lesh RW, et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv Ther. 2019;36(10):2638–2678.
   PubMed Web of Science ®Google Scholar
• Jóźwicki W, Brożyna AA, Siekiera J, et al. Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal. Oncotarget. 2016;7(10):11450–11462.
   PubMedGoogle Scholar
• Gu-Trantien C, Loi S, Garaud S, et al. CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123(7):2873–2892.
   PubMed Web of Science ®Google Scholar
• Winerdal ME, Krantz D, Hartana CA, et al. Urinary bladder cancer tregs suppress MMP2 and potentially regulate invasiveness. Cancer Immunol Res. 2018;6(5):528–538.
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365.
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2017;168(3):542.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
   PubMed Web of Science ®Google Scholar
• Pouessel D, Neuzillet Y, Mertens LS, et al. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. Ann Oncol. 2016;27(7):1311–1316.
   PubMed Web of Science ®Google Scholar
• Guancial EA, Werner L, Bellmunt J, et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014;3(4):835–844.
   PubMed Web of Science ®Google Scholar
• Ahmad F, Mahal V, Verma G, et al. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients. Cancer Rep (Hoboken). 2018;1(3):e1130.
   PubMedGoogle Scholar
• Ciccarese C, Massari F, Blanca A, et al. Tp53 and its potential therapeutic role as a target in bladder cancer. Expert Opin Ther Targets. 2017;21(4):401–414.
   PubMed Web of Science ®Google Scholar
• Wu G, Wang F, Li K, et al. Significance of TP53 mutation in bladder cancer disease progression and drug selection. PeerJ. 2019;7:e8261.
   PubMed Web of Science ®Google Scholar
• How CW, Ong YS, Low SS, et al. How far have we explored fungi to fight cancer? Semin Cancer Biol. 2021. DOI:10.1016/j.semcancer.2021.03.009.
   PubMed Web of Science ®Google Scholar
• Shin Low S, Pan Y, Ji D, et al. Smartphone-based portable electrochemical biosensing system for detection of circulating microRNA-21 in saliva as a proof-of-concept. Sens Actuators B Chem. 2020;308:127718.
   Web of Science ®Google Scholar